Literature DB >> 17279087

Genetic and pharmacological approaches to evaluate the interaction between the cannabinoid and cholinergic systems in cognitive processes.

S A Bura1, A Castañé, C Ledent, O Valverde, R Maldonado.   

Abstract

BACKGROUND AND
PURPOSE: The objective of this study was to investigate the possible interactions between the cannabinoid and cholinergic systems in memory and learning processes by using genetic and pharmacological approaches in two different behavioural models, the active avoidance and the object recognition test. EXPERIMENTAL APPROACH: The effects induced by nicotine, physostigmine and scopolamine were studied in CB(1) receptor knockout and wild-type mice in the active avoidance paradigm. In addition, the effects of pretreatment with the CB(1) receptor antagonist rimonabant were evaluated on the responses induced by nicotine in the active avoidance and the object recognition tasks in wild-type mice. KEY
RESULTS: Nicotine (0.5 mg kg(-1) s.c.) did not modify the performance of CB(1) knockout and wild-type mice in this model, whereas scopolamine (0.5 mgkg(-1) i.p.) impaired the performance in both genotypes. Physostigmine (0.1 mg kg(-1) i.p.) increased the active avoidance performance in wild-type but not in CB(1) knockout mice. Rimonabant (0.3, 1, 3, and 10 mg kg(-1)) did not modify the performance in the active avoidance test, given alone or co-administered with nicotine. In contrast, nicotine enhanced the performance in the object recognition task but this response was attenuated by rimonabant co-administration. CONCLUSIONS AND IMPLICATIONS: The present findings revealed that the cognitive effects of nicotine and physostigmine were attenuated in the absence of CB(1) receptor activity. Scopolamine effects were independent from CB(1) receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17279087      PMCID: PMC2013866          DOI: 10.1038/sj.bjp.0707152

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  51 in total

1.  Perspectives: neuroscience. Remembrance of things past.

Authors:  D L Schacter; A D Wagner
Journal:  Science       Date:  1999-09-03       Impact factor: 47.728

Review 2.  Hippocampus and context in classical conditioning.

Authors:  P C Holland; M E Bouton
Journal:  Curr Opin Neurobiol       Date:  1999-04       Impact factor: 6.627

3.  The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide.

Authors:  P E Mallet; R J Beninger
Journal:  Psychopharmacology (Berl)       Date:  1998-11       Impact factor: 4.530

4.  Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice.

Authors:  H Meziane; J C Dodart; C Mathis; S Little; J Clemens; S M Paul; A Ungerer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

5.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Authors:  Jean-Pierre Després; Alain Golay; Lars Sjöström
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

6.  The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze.

Authors:  Reinaldo Naoto Takahashi; Fabrício Alano Pamplona; Marcelo Soares Fernandes
Journal:  Neurosci Lett       Date:  2005-02-16       Impact factor: 3.046

7.  Effects of housing and nicotine on shuttle-box avoidance in male NMRI mice.

Authors:  Inés Moragrega; M Carmen Carrasco; Rosa Redolat
Journal:  Behav Brain Res       Date:  2005-11-07       Impact factor: 3.332

8.  Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

Authors:  C Ledent; O Valverde; G Cossu; F Petitet; J F Aubert; F Beslot; G A Böhme; A Imperato; T Pedrazzini; B P Roques; G Vassart; W Fratta; M Parmentier
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

9.  Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.

Authors:  G L Gessa; M A Casu; G Carta; M S Mascia
Journal:  Eur J Pharmacol       Date:  1998-08-21       Impact factor: 4.432

10.  Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice.

Authors:  Graciela N Balerio; Ester Aso; Fernando Berrendero; Patricia Murtra; Rafael Maldonado
Journal:  Eur J Neurosci       Date:  2004-11       Impact factor: 3.386

View more
  6 in total

1.  Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice.

Authors:  Jesús Planagumà; Frank Leypoldt; Francesco Mannara; Javier Gutiérrez-Cuesta; Elena Martín-García; Esther Aguilar; Maarten J Titulaer; Mar Petit-Pedrol; Ankit Jain; Rita Balice-Gordon; Melike Lakadamyali; Francesc Graus; Rafael Maldonado; Josep Dalmau
Journal:  Brain       Date:  2014-11-11       Impact factor: 13.501

2.  Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Authors:  Stephen A Varvel; Laura E Wise; Aron H Lichtman
Journal:  Drug Dev Res       Date:  2009-12-01       Impact factor: 4.360

Review 3.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

4.  The effects of acute, chronic, and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice.

Authors:  Justin W Kenney; Michael D Adoff; Derek S Wilkinson; Thomas J Gould
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

5.  LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory.

Authors:  Mar Petit-Pedrol; Josefine Sell; Jesús Planagumà; Francesco Mannara; Marija Radosevic; Holger Haselmann; Mihai Ceanga; Lidia Sabater; Marianna Spatola; David Soto; Xavier Gasull; Josep Dalmau; Christian Geis
Journal:  Brain       Date:  2018-11-01       Impact factor: 13.501

6.  Bimodal control of fear-coping strategies by CB₁ cannabinoid receptors.

Authors:  Mathilde Metna-Laurent; Edgar Soria-Gómez; Danièle Verrier; Martina Conforzi; Pierrick Jégo; Pauline Lafenêtre; Giovanni Marsicano
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.